Biopartnerships - Pharmaceutical Executive

ADVERTISEMENT

Biopartnerships

Oiling the Engines of Invention

October 1, 2004

Big Pharma execs bring to biotech the knowledge of what it takes to make something a commercial success—not getting to market, but to Phase I.

Avoiding the Train Wreck

October 1, 2004

The "due diligence framework" is an efficient process. But efficient is not the same as quick and easy. There are no shortcuts. The framework minimizes resource commitments and disruptions to ongoing programs and helps each side learn what it needs to know. In six steps, it converts the typical due diligence root canal into a painless filling.

Fruitful and Prosperous

October 1, 2004

EVERYONE KNOWS THAT ROCHE WAS, AND ARGUABLY STILL is, the driver of Genentech's success. But not everyone knows that Roche owns a majority stake in the biotech behemoth, as it does in Japanese powerhouse Chugai. And that's by design. Roche's management has long held that the best way to derive good and lasting results from its smaller partners is to let them do what they do best and leave them alone while they do it. That philosophy has served them well, especially when revenues of some of their codeveloped and comarketed blockbuster products are considered. Just two, Genentech's Herceptin (trastuzumab) and Chugai's Epogin (epoetin beta), have earned billions.

The Human Side of Partnerships

October 1, 2004

He potential for frustration, time-wasting, and bad feelings between pharma and biotech partners is enormous. That some successful decisions are made under these circumstances is something of a miracle.

Private Industry's Most Eligible

October 1, 2004

Companies should dig in a more attractive mine where very few other companies are looking.

A Decade (and 1/2) of Deals

October 1, 2004

More than half the deals made by pharma are with companies based in the US, 28 percent in Europe, and 15 percent Japan.

ADVERTISEMENT

Click here